128 related articles for article (PubMed ID: 38275079)
1. Anchoring of hyaluronan glycocalyx to CD44 reduces sensitivity of HER2-positive gastric cancer cells to trastuzumab.
Chen S; Zhang G; Liu Y; Yang C; He Y; Guo Q; Du Y; Gao F
FEBS J; 2024 Apr; 291(8):1719-1731. PubMed ID: 38275079
[TBL] [Abstract][Full Text] [Related]
2. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.
Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS
Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840
[TBL] [Abstract][Full Text] [Related]
3. Dual-targeting hybrid nanoparticles for the delivery of SN38 to Her2 and CD44 overexpressed human gastric cancer.
Yang Z; Luo H; Cao Z; Chen Y; Gao J; Li Y; Jiang Q; Xu R; Liu J
Nanoscale; 2016 Jun; 8(22):11543-58. PubMed ID: 27203688
[TBL] [Abstract][Full Text] [Related]
4. CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells.
Boulbes DR; Chauhan GB; Jin Q; Bartholomeusz C; Esteva FJ
Breast Cancer Res Treat; 2015 Jun; 151(3):501-13. PubMed ID: 25971596
[TBL] [Abstract][Full Text] [Related]
5. Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer.
Seo AN; Lee HJ; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
Br J Cancer; 2016 May; 114(10):1109-16. PubMed ID: 27115469
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling.
Cui Y; Li SB; Peng XC; Wu J; Fu GH
Dig Dis Sci; 2015 Dec; 60(12):3631-41. PubMed ID: 26173505
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
[TBL] [Abstract][Full Text] [Related]
8. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab.
Eto K; Iwatsuki M; Watanabe M; Ida S; Ishimoto T; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
Ann Surg Oncol; 2014 Jan; 21(1):343-50. PubMed ID: 24154840
[TBL] [Abstract][Full Text] [Related]
9. Cdc42-driven endosomal cholesterol transport promotes collateral resistance in HER2-positive gastric cancer.
Liang B; Wu Q; Wang Y; Shi Y; Sun F; Huang Q; Li G; Liu Y; Zhang S; Xu X; Yao G; Peng J; Zhai X; Wu J; Tan Y; Wu Z; Zhou R; Li S; Wu J; Yang M; Liao W; Shi M
Cancer Lett; 2024 Apr; 587():216702. PubMed ID: 38336288
[TBL] [Abstract][Full Text] [Related]
10. GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.
Gardaneh M; Shojaei S; Kaviani A; Behnam B
Breast Cancer Res Treat; 2017 Apr; 162(2):231-241. PubMed ID: 28116540
[TBL] [Abstract][Full Text] [Related]
11. Increasing HER2 α2,6 sialylation facilitates gastric cancer progression and resistance via the Akt and ERK pathways.
Liu N; Zhu M; Linhai Y; Song Y; Gui X; Tan G; Li J; Liu Y; Deng Z; Chen X; Wang J; Jia L; He X; Wang X; Lin S
Oncol Rep; 2018 Nov; 40(5):2997-3005. PubMed ID: 30226606
[TBL] [Abstract][Full Text] [Related]
12. Precision Therapy of Recurrent Breast Cancer through Targeting Different Malignant Tumor Cells with a HER2/CD44-Targeted Hydrogel Nanobot.
Chen J; Li J; Sun X; Lu H; Liu K; Li Z; Guan J; Song H; Wei W; Ge Y; Fan Q; Bao W; Ma B; Du Z
Small; 2023 Sep; 19(37):e2301043. PubMed ID: 37154208
[TBL] [Abstract][Full Text] [Related]
13. Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2.
Wu J; Zhao Q; Zhao Y; Zhang X; Tian Y; Guo Z
Sci Rep; 2021 Mar; 11(1):6993. PubMed ID: 33772068
[TBL] [Abstract][Full Text] [Related]
14. miR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer.
Guo J; Zhong X; Tan Q; Yang S; Liao J; Zhuge J; Hong Z; Deng Q; Zuo Q
Cell Death Dis; 2021 Jul; 12(7):696. PubMed ID: 34257270
[TBL] [Abstract][Full Text] [Related]
15. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
[TBL] [Abstract][Full Text] [Related]
16. Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Corominas-Faja B; Cufí S; Vazquez-Martin A; Martin-Castillo B; Iglesias JM; López-Bonet E; Martin ÁG; Menendez JA
Cell Cycle; 2012 Nov; 11(21):4020-32. PubMed ID: 22992620
[TBL] [Abstract][Full Text] [Related]
17. Thioridazine reverses trastuzumab resistance in gastric cancer by inhibiting S-phase kinase associated protein 2-mediated aerobic glycolysis.
Yang ZY; Zhao YW; Xue JR; Guo R; Zhao Z; Liu HD; Ren ZG; Shi M
World J Gastroenterol; 2023 Dec; 29(45):5974-5987. PubMed ID: 38130998
[TBL] [Abstract][Full Text] [Related]
18. Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.
Mezynski MJ; Farrelly AM; Cremona M; Carr A; Morgan C; Workman J; Armstrong P; McAuley J; Madden S; Fay J; Sheehan KM; Kay EW; Holohan C; Elamin Y; Rafee S; Morris PG; Breathnach O; Grogan L; Hennessy BT; Toomey S
J Transl Med; 2021 May; 19(1):184. PubMed ID: 33933113
[TBL] [Abstract][Full Text] [Related]
19. Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers.
Rao Y; Samuels Z; Carter LM; Monette S; Panikar SS; Pereira PMR; Lewis JS
Proc Natl Acad Sci U S A; 2023 Apr; 120(14):e2220413120. PubMed ID: 36972439
[TBL] [Abstract][Full Text] [Related]
20. EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44.
Pályi-Krekk Z; Barok M; Kovács T; Saya H; Nagano O; Szöllosi J; Nagy P
Cancer Lett; 2008 May; 263(2):231-42. PubMed ID: 18276068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
